Denali Therapeutics Revenue and Competitors

Claim your profile

Location

$347M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Denali Therapeutics's estimated annual revenue is currently $353M per year.(i)
  • Denali Therapeutics received $130.0M in venture funding in August 2016.
  • Denali Therapeutics's estimated revenue per employee is $693,438
  • Denali Therapeutics's total funding is $347M.
  • Denali Therapeutics's current valuation is $4.3B. (January 2022)

Employee Data

  • Denali Therapeutics has 509 Employees.(i)
  • Denali Therapeutics grew their employee count by 12% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Denali Therapeutics Inc. (Denali) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS and others. Denali was founded by scientists, industry experts and investors who share the vision that recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new translational medicine tools, offer an unprecedented opportunity to discover and develop effective medicines. Denali is rigorously pursuing a science-driven approach to translational medicine and clinical development. Founding investors include Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund (represented by Crestline Investors).

keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power

$347M

Total Funding

509

Number of Employees

$353M

Revenue (est)

12%

Employee Growth %

$4.3B

Valuation

N/A

Accelerator

Denali Therapeutics News

2022-04-20 - Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

For Denali Therapeutics Inc.The Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently...

2022-04-13 - $26.10 Million in Sales Expected for Denali Therapeutics Inc ...

Brokerages expect Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) to post sales of $26.10 million for the current fiscal quarter,...

2022-04-13 - Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average ...

Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of “Buy” from Brokerages. Posted by admin on Apr 16th, 2022.

2021-09-29 - Denali Therapeutics : Announces Upcoming Presentations on EIF2B Activator DNL343 and RIPK1 Inhibitor SAR443820/DNL788 at the 2021 Annual Northeast Amyotrophic Lateral Sclerosis (NEALS) Meeting

Denali to present results from Phase 1 healthy volunteer study of EIF2B activator DNL343 Sanofi to present Phase 2 study plans in ALS for RIPK1 inhibitor SAR443820 Denali to host analyst and investor webinar on October 6, at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Sept. 29, 2021 (GL ...

2019-09-08 - GSA Capital Partners LLP Boosts Holdings in Denali ...

GSA Capital Partners LLP increased its holdings in Denali Therapeutics Inc (NASDAQ:DNLI) by 174.3% in the second quarter, according to its ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$111.5M51444%$1.1B
#2
$192.9M53210%N/A
#3
$135.8M62624%$681.3M
#4
$12.8M660-7%$59.3M
#5
$179.9M66720%$532.5M

Denali Therapeutics Funding

DateAmountRoundLead InvestorsReference
2015-05-15$217.0MAArticle
2016-08-26$130.0MBGenentechArticle